NCT00782093View on ClinicalTrials.gov

A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Age-related Macular Degeneration
Interventions
DRUG

volociximab

volociximab intravitreal injection

Sponsors
All Listed Sponsors
lead

Ophthotech Corporation

INDUSTRY

NCT00782093 - A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration | Biotech Hunter | Biotech Hunter